|
30 Companies |
|
33 Products |
|
33 Products |
|
36 Mechanisms of Action |
|
0 Trials |
|
51 News |
|
| 12» |
- | decitabine / Generic mfg.
Trial completion: Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 19, 2019
P2, N=546, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- | Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=220, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Aug 2011 --> Jan 2012 | Trial primary completion date: Sep 2011 --> Feb 2012
- | cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial completion, Trial primary completion date: Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 19, 2017
P1, N=53, Completed, Sponsor: Wake Forest University Health Sciences
Not yet recruiting --> Completed | Initiation date: Aug 2011 --> Jan 2012 | Trial primary completion date: Sep 2011 --> Feb 2012 Active, not recruiting --> Completed | Trial primary completion date: Nov 2008 --> Jan 2015
- ||| Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Trial completion, Trial primary completion date: Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 (clinicaltrials.gov) - May 19, 2016
P=N/A, N=1000, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Nov 2008 --> Jan 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=250, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Trial completion, Trial primary completion date: Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=98, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- cytarabine / Generic mfg.
Biomarker, Trial completion: S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=310, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed
- decitabine / Generic mfg.
Trial primary completion date: Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 27, 2015
P2, N=546, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jan 2013 --> Jan 2011
- Trial termination: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 20, 2015
P1, N=13, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2013 --> Jan 2011 Active, not recruiting --> Terminated; Inadequate accrual rate
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 9, 2015
P1, N=24, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Terminated; Inadequate accrual rate Active, not recruiting --> Completed
- Enrollment change, Trial primary completion date: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - May 21, 2015
P1, N=13, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=18 --> 13 | Trial primary completion date: Dec 2014 --> Mar 2015
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML (clinicaltrials.gov) - Mar 28, 2015
P3, N=637, Completed, Sponsor: Southwest Oncology Group
N=18 --> 13 | Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia (clinicaltrials.gov) - May 25, 2014
P1/2, N=95, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- bortezomib / Generic mfg.
Trial completion, IO biomarker: Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia (clinicaltrials.gov) - May 12, 2014
P2, N=52, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment change: Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 5, 2014
P2, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=46 --> 25
- | Istodax (romidepsin) / Astellas, BMS
Trial completion: Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders (clinicaltrials.gov) - Feb 22, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
N=46 --> 25 Suspended --> Completed
- ||||||| Onrigin (laromustine) / Vion
Trial completion: Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P3, N=420, Completed, Sponsor: Vion Pharmaceuticals
Suspended --> Completed Suspended --> Completed
- | tanespimycin (BMS-722782) / BMS
Trial completion: Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 22, 2014
P1, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: XK469R in Treating Patients With Refractory Hematologic Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Completed
- | arsenic trioxide / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion: Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P1, N=61, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Triapine (3-AP) / Vion, Northwestern University
Trial completion: 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed No longer recruiting --> Completed
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, patupilone (EPO 906) / Novartis
Trial completion: Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
No longer recruiting --> Completed Recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=125, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=7, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Biomarker, Enrollment change: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 12, 2014
P=N/A, N=250, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=200 --> 250
- ||| Biomarker, Enrollment open: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 12, 2014
P=N/A, N=250, Recruiting, Sponsor: Children's Oncology Group
N=200 --> 250 Active, not recruiting --> Recruiting
- bortezomib / Generic mfg.
Enrollment change, IO biomarker: Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 17, 2013
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting N=90 --> 52
- bortezomib / Generic mfg.
Enrollment closed, IO biomarker: Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 17, 2013
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=90 --> 52 Completed --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Trial completion: Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 3, 2013
P2, N=60, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed --> Active, not recruiting Active, not recruiting --> Completed
- imatinib / Generic mfg., cladribine / Generic mfg., cytarabine / Generic mfg.
Trial completion, Combination therapy: Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Oct 13, 2013
P1, N=18, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed Recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 6, 2013
P2, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Terminated --> Completed
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial termination, Combination therapy, Epigenetic controller, Metastases: Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 17, 2013
P1, N=44, Terminated, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Active, not recruiting --> Terminated
- | Zarnestra (tipifarnib) / Kura Oncology, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion: Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Aug 22, 2013
P2/3, N=2000, Completed, Sponsor: The University of New South Wales
Active, not recruiting --> Terminated Recruiting --> Completed
- || Enrollment closed: Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=98, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- bortezomib / Generic mfg.
Trial termination: 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Jun 2, 2013
P1, N=74, Terminated, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting Completed --> Terminated
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial termination: Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jun 2, 2013
P1, N=88, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Active, not recruiting --> Terminated
- Enrollment closed: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - May 6, 2013
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial completion: Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (clinicaltrials.gov) - Apr 9, 2013
P1, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial termination: Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 22, 2013
P2, N=120, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Terminated; Administratively complete.
- Cilcane (cilengitide) / Iceni Pharma
Trial termination: Cilengitide in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 22, 2013
P2, N=70, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. Completed --> Terminated; Administratively complete.
- sorafenib / Generic mfg.
Trial completion: Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jan 7, 2013
P1, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. Terminated --> Completed
- cytarabine / Generic mfg.
Biomarker, Enrollment closed: S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=310, Active, not recruiting, Sponsor: Southwest Oncology Group
Terminated --> Completed Not yet recruiting --> Active, not recruiting
- | Trial completion: Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 10, 2012
P3, N=720, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 14, 2012
P=N/A, N=100, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Completed
- sorafenib / Generic mfg.
Enrollment change: Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Nov 7, 2012
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed N=55 --> 36
- cytarabine / Generic mfg., clofarabine / Generic mfg.
New P2 trial: A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 31, 2012
P2, N=39, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Enrollment change: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - May 23, 2012
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=55 --> 36 N=55 --> 18
- daunorubicin / Generic mfg.
Enrollment change: S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=71, Completed, Sponsor: Southwest Oncology Group
N=55 --> 18 N=55 --> 71
- daunorubicin / Generic mfg.
Trial completion: S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=71, Completed, Sponsor: Southwest Oncology Group
N=55 --> 71 Active, not recruiting --> Completed